The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,636,696 in first-year total cost, median $354,252.
Most frequent study sections
- Special Emphasis Panel[ZDK1 GRB-S (J2)]2
- Special Emphasis Panel[ZDK1 GRB-S (M3)]2
- Special Emphasis Panel[ZDK1 GRB-S (O3)]1
Most frequent institutions
- ARBOR RESEARCH COLLABORATIVE FOR HEALTH1
- EMORY UNIVERSITY1
- JOSLIN DIABETES CENTER1
- MASSACHUSETTS GENERAL HOSPITAL1
- UNIVERSITY OF COLORADO DENVER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Cardiac Autoimmunity as a Mediator of Cardiovascular Outcomes in Type 1 Diabetes1R01DK125677-01 | LIPES, MYRA A | JOSLIN DIABETES CENTER, MA | $392,786 | ZDK1 |
| 2020 | Biomarker Discovery for Nonalcoholic Fatty Liver Disease in Children1R01DK125701-01A1 | VOS, MIRIAM B. | EMORY UNIVERSITY, GA | $354,252 | ZDK1 |
| 2020 | Protein Carbamylation and the Progression and Complications of CKD1R01DK124453-01 | KALIM, SAHIR | MASSACHUSETTS GENERAL HOSPITAL, MA | $286,368 | ZDK1 |
| 2020 | Identification of biomarker signatures of subtypes of LUTS and their response to treatments using samples from LURN study1R01DK125251-01 | ANDREEV, VICTOR P. | ARBOR RESEARCH COLLABORATIVE FOR HEALTH, MI | $217,655 | ZDK1 |
| 2018 | Discovery and validation of biomarkers of cardiovascular complications in type 1 diabetes1R01DK116731-01 | SNELL-BERGEON, JANET KATHLEENZHANG, QIBIN | UNIVERSITY OF COLORADO DENVER, CO | $385,635 | ZDK1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.